01-25-02

PTO/SB/05 (03-01) Approved for use through 10/31/2002 OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE REG 900A

Please type a plus sign (+) inside this box —

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. Nicholas W. Gale First Inventor Methods of Imaging and Targeting

Express Mail Label No. ET712521759US (Only for new nonprovisional applications under 37 CFR 1 53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8 Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1 27. (if applicable, all necessary) Specification [Total Pages X Computer Readable Form (CRF) (preferred arrangement set forth below) - Descriptive title of the invention Specification Sequence Listing on. Cross Reference to Related Applications CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, 1 i. [_] paper or a computer program listing appendix Statements verifying identity of above copies Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) Power of 37 CFR 3.73(b) Statement - Abstract of the Disclosure Attorney (when there is an assignee) 11 English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure 12. [Total Pages 5. Oath or Declaration Citations Statement (IDS)/PTO-1449 Preliminary Amendment Newly executed (original or copy) Copy from a prior application (37 CFR 1 63 (d)) Return Receipt Postcard (MPEP 503) 14 (for continuation/divisional with Box 18 completed) (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) DELETION OF INVENTOR(S) 15 Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 1.63(d)(2) and 1 33(b) or its equivalent. Unexecuted Declaration and Other: Power of Attorney..... Application Data Sheet. See 37 CFR 1.76 17 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: 60 / 264,406 X Continuation Divisional Continuation-in-part (CIP) of pnor application No.: Prior application information Examiner None assigned Group Art Unit None assigned For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Correspondence address below or Customer Number or Bar Code Label (Insert Customer No. of Attach bar code label here) Name Linda O. Palladino Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road <u>Address</u> State Zip Code City Tarrytown New York 10591 914-345-7721 United States Country 914-345-7400 Fax Telephone Registration No. (Attorney/Agent) Name (Print/Type) 45,636 Palladino Signature Date January 23, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

PTO/SB/17 (10-01)
Approved for use through 10/31/2002, OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision

Name (Print/Type)

Signature

Linda, O. Palladino

(\$) 2,292.

Complete if Known		
Application Number	Not Yet Known	
Filing Date	Filed Herewith	
First Named inventor	Nicholas W. Gale	
Examiner Name	Not Yet Known	
Group Art Unit	Not Yet Known	
Attorney Docket No	REG 900A	

METHOD OF PAYMENT	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES			
Deposit	Large Small Entity Entity			
Account Number 18-0650		Fee Paid		
Deposit Account Name Regeneron Pharmaceuticals, Inc.	105 130 205 65 Surcharge - late filing fee or oath			
Charge Any Additional Fee Required	127 50 227 25 Surcharge - late provisional filing fee or cover sheet			
Under 37 CFR 1 16 and 1 17 Applicant claims small entity status	139 130 139 130 Non-English specification			
See 37 CFR 127	147 2 520 147 2.520 For filing a request for ex parte reexamination			
2. Payment Enclosed: Check Credit card Money Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
	115 110 215 55 Extension for reply within first month			
1. BASIC FILING FEE Large Entity Small Entity	116 400 216 200 Extension for reply within second month			
Fee Fee Fee Fee Description	117 920 217 460 Extension for reply within third month			
Code (\$) Code (\$) Fee Paid	118 1,440 218 720 Extension for reply within fourth month			
101 740 201 370 Utility filing fee 740.	128 1,960 228 980 Extension for reply within fifth month			
106 330 206 165 Design filing fee 107 510 207 255 Plant filing fee	119 320 219 160 Notice of Appeal			
	120 320 220 160 Filing a brief in support of an appeal			
108 740 208 370 Reissue filing fee 114 160 214 80 Provisional filing fee	121 280 221 140 Request for oral hearing			
114 160 214 60 Provisional lining fee	138 1,510 138 1,510 Petition to institute a public use proceeding			
SUBTOTAL (1) (\$) 740.	140 110 240 55 Petition to revive - unavoidable			
2. EXTRA CLAIM FEES	141 1,280 241 640 Petition to revive - unintentional			
Total Claims 72 -20** = 52 X 18. = 936.	1			
	143 460 243 230 Design issue fee			
Independent $\frac{7}{2}$ - 3** = $\frac{4}{4}$ X $\frac{84}{4}$ = $\frac{336}{4}$	144 620 244 310 Plant issue fee			
Multiple Dependent 280. = 280.	122 130 122 130 Petitions to the Commissioner			
	123 50 123 50 Processing fee under 37 CFR 1.17(q)			
Large Entity Small Entity Fee Fee Fee Fee Description	126 180 126 180 Supmission of Information Disclosure Stmt			
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)			
102 84 202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection (37 CFR § 1 129(a))			
104 280 204 140 Multiple dependent claim, if not paid 109 84 209 42 ** Reissue independent claims	149 740 249 370 For each additional invention to be examined (37 CFR § 1.129(b))			
over original patent 110 18 210 9 ** Reissue claims in excess of 20	179 740 279 370 Request for Continued Examination (RCE)			
and over original patent	169 900 169 900 Request for expedited examination of a design application			
SUBTOTAL (2) (\$) 1,552.	Other fee (specify)			
**or number previously paid, if greater; For Reissues, see above *Reduced by Basic Fling Fee Paid SUBTOTAL (3)				
SUBMITTED BY Complete (if applicable)				

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Registration No

45,636

(Attorney/Agent)

Telephone

Date

914-345-7400

January 23, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OF COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.